Free shipping on all orders over $ 500

Patisiran

Cat. No. M40952

All AbMole products are for research use only, cannot be used for human consumption.

Patisiran Structure

Price and Availability

For this product's availability, delivery time and price, please email inquiry@abmole.com directly or click the "Inquiry Now" button below.


Quality Control & Documentation
Biological Activity

Patisiran is a small double-stranded interfering RNA that targets sequences within the Transthyretin (TTR) messenger RNA and specifically inhibits hepatic synthesis of mutant and wild-type TTR. It can be used to study hereditary TTR amyloidosis.

Chemical Information
CAS Number 1420706-45-1
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Adam Ioannou et al. Heart Int. Patisiran for the Treatment of Transthyretin-mediated Amyloidosis with Cardiomyopathy

[2] Yuta Suzuki et al. Drug Metab Pharmacokinet. Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs

[3] Sheridan M Hoy. Drugs. Patisiran: First Global Approval

[4] David Adams et al. N Engl J Med. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

Related Transthyretin (TTR) Products
Tafamidis

Tafamidis is a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade, with EC50s of 2.7-3.2 μM to the mutumant homotetramers V30M-TTR, V122I-TTR and wild type WT-TTR.

A 1120

A 1120 is a high-affinity antagonist of retinol-binding protein 4 (RBP4) with a Ki value of 8.3 nM that disrupts the interaction between RBP4 and its conjugate transthyretin.

Acoramidis hydrochloride

Acoramidis (AG10) hydrochloride is an orally active, selective stabilizer of the thyroxine transporter (TTR (transthyretin)) that is effective against both wild-type and V1221 mutant types. Acoramidis (AG10) hydrochloride can be used for the study of transthyroxine amyloidosis.

Acoramidis

Acoramidis (AG10) is an orally active, selective stabilizer of the thyroxine transporter (TTR) that is effective against both wild-type and V1221 mutant types.

WT-TTR inhibitor 1

WT-TTR inhibitor 1 is a wild-type Transthyretin (WT-TTR) inhibitor with 29.05% inhibition at 100 μM.

  Catalog
Abmole Inhibitor Catalog




Keywords: Patisiran supplier, Transthyretin (TTR), inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.